Today the National Association of Medicaid Directors sent the attached letter to the leaders of the Senate Finance and HELP and House Energy & Commerce and Ways & Means committees regarding the current situation with break through prescription drug treatments. The letter addresses the challenges presented by new hepatitis C treatments. It focuses on issues pertinent to state Medicaid programs, though it recognizes this issue impacts all government programs and other payers as well as patients. It also calls on Members of Congress to begin a dialogue on break through drug pricing issues and to advance pragmatic solutions that balance the needs of patients and the costs for Medicaid.
- In the NAMD newsletter: Brian Neale leaves CMS; Work Requirement Lawsuit; Indiana Waiver Extended; Happenings on the Hill; January MACPAC. February 7, 2018
- In the newsletter: New guidance on community engagement; Kentucky work requirement waiver approved; MedPAC & MACPAC, Beneficiaries Dually Eligible for Medicare and Medicaid. January 23, 2018
- Happy New Year! In the newsletter we cover Healthcare choice and competition; substance abuse; Mississippi Section 1115 demonstration; opioids; Hill happenings. January 9, 2018